Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Logo

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd.

300501.SZ

(3.0)
Stock Price

14,03 CNY

3.55% ROA

5.48% ROE

29.92x PER

Market Cap.

2.947.673.764,00 CNY

46.96% DER

0.96% Yield

9.72% NPM

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Stock Analysis

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (44%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

5 ROE

ROE in an average range (6.37%) suggests satisfactory profitability and decent utilization of shareholders' equity.

6 ROA

The stock's ROA (3.65%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

7 PBV

The stock's PBV ratio (1.61x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

8 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (165) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Revenue
Year Revenue Growth
2011 149.003.104
2012 210.237.307 29.13%
2013 277.366.830 24.2%
2014 289.849.722 4.31%
2015 293.978.431 1.4%
2016 301.275.888 2.42%
2017 375.617.177 19.79%
2018 507.195.935 25.94%
2019 621.030.370 18.33%
2020 713.784.961 12.99%
2021 856.857.795 16.7%
2022 1.012.601.235 15.38%
2023 920.818.612 -9.97%
2023 1.010.390.052 8.87%
2024 1.155.753.220 12.58%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2011 0
2012 10.136.178 100%
2013 15.703.060 35.45%
2014 16.156.769 2.81%
2015 16.778.496 3.71%
2016 16.362.021 -2.55%
2017 16.865.268 2.98%
2018 23.264.042 27.5%
2019 26.436.702 12%
2020 24.294.381 -8.82%
2021 32.877.686 26.11%
2022 44.490.523 26.1%
2023 40.626.211 -9.51%
2023 47.573.465 14.6%
2024 51.105.928 6.91%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2011 16.212.701
2012 2.509.033 -546.17%
2013 3.295.447 23.86%
2014 2.828.766 -16.5%
2015 5.172.703 45.31%
2016 5.901.044 12.34%
2017 12.810.207 53.93%
2018 13.164.615 2.69%
2019 27.120.073 51.46%
2020 16.472.130 -64.64%
2021 12.923.652 -27.46%
2022 14.886.671 13.19%
2023 164.237.643 90.94%
2023 14.545.789 -1029.11%
2024 -34.787.861 141.81%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. EBITDA
Year EBITDA Growth
2011 26.703.798
2012 48.153.477 44.54%
2013 63.008.779 23.58%
2014 68.617.942 8.17%
2015 76.054.450 9.78%
2016 83.003.397 8.37%
2017 90.614.580 8.4%
2018 105.438.252 14.06%
2019 115.924.936 9.05%
2020 164.266.691 29.43%
2021 167.124.095 1.71%
2022 182.460.960 8.41%
2023 228.523.625 20.16%
2023 168.508.230 -35.62%
2024 218.486.520 22.87%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Gross Profit
Year Gross Profit Growth
2011 49.948.527
2012 71.124.755 29.77%
2013 95.100.076 25.21%
2014 101.653.107 6.45%
2015 108.047.860 5.92%
2016 116.556.041 7.3%
2017 140.481.083 17.03%
2018 165.702.752 15.22%
2019 193.506.761 14.37%
2020 243.810.351 20.63%
2021 247.046.281 1.31%
2022 271.666.736 9.06%
2023 277.541.601 2.12%
2023 284.373.642 2.4%
2024 336.384.816 15.46%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Net Profit
Year Net Profit Growth
2011 19.791.067
2012 34.058.142 41.89%
2013 44.466.124 23.41%
2014 54.224.089 18%
2015 58.767.414 7.73%
2016 64.603.521 9.03%
2017 65.811.232 1.84%
2018 66.165.096 0.53%
2019 66.976.219 1.21%
2020 102.903.824 34.91%
2021 104.645.765 1.66%
2022 102.461.491 -2.13%
2023 192.475.940 46.77%
2023 85.441.741 -125.27%
2024 139.362.580 38.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 1 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 0 0%
2023 0 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Free Cashflow
Year Free Cashflow Growth
2011 -15.169.092
2012 22.290.523 168.05%
2013 22.739.826 1.98%
2014 61.398.535 62.96%
2015 38.041.067 -61.4%
2016 -23.758.228 260.12%
2017 9.312.211 355.13%
2018 -40.198.633 123.17%
2019 12.589.313 419.31%
2020 -61.188.608 120.57%
2021 -102.001.726 40.01%
2022 -210.180.601 51.47%
2023 -157.147.049 -33.75%
2023 -57.702.500 -172.34%
2024 -32.137.175 -79.55%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Operating Cashflow
Year Operating Cashflow Growth
2011 0
2012 26.495.965 100%
2013 28.403.104 6.71%
2014 62.805.425 54.78%
2015 53.274.730 -17.89%
2016 33.462.320 -59.21%
2017 55.089.703 39.26%
2018 27.489.667 -100.4%
2019 95.878.082 71.33%
2020 77.485.971 -23.74%
2021 139.639.384 44.51%
2022 136.957.656 -1.96%
2023 141.675.907 3.33%
2023 0 0%
2024 10.938.322 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Capital Expenditure
Year Capital Expenditure Growth
2011 15.169.092
2012 4.205.442 -260.7%
2013 5.663.278 25.74%
2014 1.406.889 -302.54%
2015 15.233.663 90.76%
2016 57.220.548 73.38%
2017 45.777.491 -25%
2018 67.688.300 32.37%
2019 83.288.768 18.73%
2020 138.674.579 39.94%
2021 241.641.110 42.61%
2022 347.138.257 30.39%
2023 298.822.956 -16.17%
2023 57.702.500 -417.87%
2024 43.075.497 -33.96%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Equity
Year Equity Growth
2011 130.807.475
2012 164.865.617 20.66%
2013 195.845.226 15.82%
2014 232.136.505 15.63%
2015 270.920.581 14.32%
2016 594.424.375 54.42%
2017 633.688.848 6.2%
2018 714.838.944 11.35%
2019 762.366.637 6.23%
2020 876.404.561 13.01%
2021 1.585.501.167 44.72%
2022 1.679.552.992 5.6%
2023 1.922.884.458 12.65%
2023 1.926.790.418 0.2%
2024 1.894.918.308 -1.68%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Assets
Year Assets Growth
2011 187.192.595
2012 220.323.154 15.04%
2013 257.077.183 14.3%
2014 288.040.463 10.75%
2015 338.832.319 14.99%
2016 683.893.061 50.46%
2017 709.874.115 3.66%
2018 942.481.268 24.68%
2019 1.234.861.456 23.68%
2020 1.405.486.674 12.14%
2021 2.264.050.337 37.92%
2022 2.305.352.111 1.79%
2023 2.986.593.236 22.81%
2023 2.906.634.012 -2.75%
2024 2.957.246.661 1.71%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Liabilities
Year Liabilities Growth
2011 56.385.120
2012 55.457.536 -1.67%
2013 61.231.956 9.43%
2014 55.903.957 -9.53%
2015 67.911.737 17.68%
2016 89.468.684 24.09%
2017 76.185.266 -17.44%
2018 227.642.324 66.53%
2019 472.494.818 51.82%
2020 529.082.113 10.7%
2021 678.549.169 22.03%
2022 625.799.118 -8.43%
2023 1.023.453.725 38.85%
2023 979.843.594 -4.45%
2024 1.008.168.270 2.81%

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
5.37
Net Income per Share
0.52
Price to Earning Ratio
29.92x
Price To Sales Ratio
2.85x
POCF Ratio
23.99
PFCF Ratio
-41.4
Price to Book Ratio
1.66
EV to Sales
3.17
EV Over EBITDA
19.05
EV to Operating CashFlow
26.18
EV to FreeCashFlow
-46.04
Earnings Yield
0.03
FreeCashFlow Yield
-0.02
Market Cap
2,95 Bil.
Enterprise Value
3,28 Bil.
Graham Number
10.49
Graham NetNet
-0.17

Income Statement Metrics

Net Income per Share
0.52
Income Quality
1.25
ROE
0.05
Return On Assets
0.03
Return On Capital Employed
0.06
Net Income per EBT
0.74
EBT Per Ebit
0.96
Ebit per Revenue
0.14
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.05
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.29
Operating Profit Margin
0.14
Pretax Profit Margin
0.13
Net Profit Margin
0.1

Dividends

Dividend Yield
0.01
Dividend Yield %
0.96
Payout Ratio
0.57
Dividend Per Share
0.15

Operating Metrics

Operating Cashflow per Share
0.65
Free CashFlow per Share
-0.37
Capex to Operating CashFlow
1.57
Capex to Revenue
0.19
Capex to Depreciation
3.29
Return on Invested Capital
0.05
Return on Tangible Assets
0.04
Days Sales Outstanding
153.01
Days Payables Outstanding
58.81
Days of Inventory on Hand
109.51
Receivables Turnover
2.39
Payables Turnover
6.21
Inventory Turnover
3.33
Capex per Share
1.02

Balance Sheet

Cash per Share
2,81
Book Value per Share
10,13
Tangible Book Value per Share
9.47
Shareholders Equity per Share
9.38
Interest Debt per Share
4.46
Debt to Equity
0.47
Debt to Assets
0.29
Net Debt to EBITDA
1.92
Current Ratio
2.77
Tangible Asset Value
1,82 Bil.
Net Current Asset Value
0,20 Bil.
Invested Capital
2146016910
Working Capital
0,77 Bil.
Intangibles to Total Assets
0.04
Average Receivables
0,40 Bil.
Average Payables
0,11 Bil.
Average Inventory
211134985.5
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Dividends
Year Dividends Growth
2016 1
2017 1 0%
2018 1 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Profile

About Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd.

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. manufactures, sells, and exports primarily pharmaceutical packaging films in China and internationally. It offers cold-forming aluminum foils, PVC/Aclar high barrier thermoformable films, tropical blister foils, lidding foils for PTP blisters, AL/PE suppository laminates, child-resistant packaging, complex laminated flexible films, AL/PE strip packs, and PVC/PVDC transparent films under the HiPack brand name. The company is headquartered in Shanghai, China.

CEO
Mr. Wuhui Lin
Employee
896
Address
No. 18, Caijiabang Road
Shanghai, 201619

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Executives & BODs

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Executives & BODs
# Name Age
1 Mr. Wuhui Lin
Chairman & GM
70
2 Mr. Hailong Ni
Chief Financial Officer & Financial Director
70
3 Mr. Qin Huang
Chief Investment Officer, Investment Director, Deputy GM & Director
70
4 Mr. Jun Li
Vice President & Deputy GM
70
5 Mr. Ping Chen
Vice President & Deputy GM
70

Shanghai Haishun New Pharmaceutical Packaging Co.,Ltd. Competitors